Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to

A del Río1, C García-de-la-Mària1, J M Entenza2

  • 1Infectious Diseases Service, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona School of Medicine, Barcelona, Catalunya, Spain.

Insights

Fosfomycin combined with imipenem or ceftriaxone shows promise for treating methicillin-resistant Staphylococcus aureus (MRSA) and glycopeptide-intermediate-resistant S. aureus (GISA) infective endocarditis (IE). These combinations were more effective than vancomycin in reducing bacterial load and sterilizing vegetations in animal models.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) and glycopeptide-intermediate-resistant S. aureus (GISA) pose significant therapeutic challenges, particularly in infective endocarditis (IE).
  • There is an urgent need for effective treatment options against these resistant strains.

Purpose of the Study:

  • To evaluate the in vitro and in vivo efficacy of fosfomycin combined with beta-lactam antibiotics against MRSA and GISA.
  • To compare the effectiveness of fosfomycin combinations with vancomycin in a preclinical model of IE.

Main Methods:

  • In vitro time-kill tests were conducted using fosfomycin combined with imipenem (FOF+IPM) against 10 MRSA/GISA isolates.
  • An aortic valve IE rabbit model was used to compare intravenous regimens: FOF+IPM, fosfomycin plus ceftriaxone (FOF+CRO), standard-dose vancomycin (VAN-SD), and high-dose vancomycin (VAN-HD).
  • Bacterial load in vegetations and the number of sterilized vegetations were assessed. Molecular studies investigated the effect on penicillin-binding protein (PBP) synthesis.

Main Results:

  • FOF+IPM demonstrated the highest in vitro activity.
  • In vivo, FOF+IPM significantly reduced MRSA-277H bacterial load in vegetations compared to VAN-SD and sterilized more vegetations (73% vs. 31%).
  • Both FOF+IPM and FOF+CRO significantly reduced GISA-ATCC 700788 load compared to VAN-SD. FOF+CRO sterilized more vegetations (53%) than vancomycin regimens (20%). FOF+IPM treatment decreased PBP1, PBP2, and PBP3 synthesis.

Conclusions:

  • Fosfomycin in combination with imipenem or ceftriaxone is a promising therapeutic strategy for MRSA and GISA IE.
  • These combinations show superior efficacy over vancomycin in preclinical models, potentially by affecting PBP synthesis.
  • Clinicians may consider FOF+IPM or FOF+CRO for treating IE caused by MRSA or GISA.

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.4K
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
33
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
58
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
99
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
330
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
46